<SEC-DOCUMENT>0001171843-25-003465.txt : 20250527
<SEC-HEADER>0001171843-25-003465.hdr.sgml : 20250527
<ACCEPTANCE-DATETIME>20250527163627
ACCESSION NUMBER:		0001171843-25-003465
CONFORMED SUBMISSION TYPE:	SD
PUBLIC DOCUMENT COUNT:		2
<RULE>
<RULE-NAME>13p-1
<ITEM>
<ITEM-NUMBER>1.01
<ITEM-PERIOD>20241231
</ITEM>
<ITEM>
<ITEM-NUMBER>1.02
<ITEM-PERIOD>20241231
</ITEM>
</RULE>
FILED AS OF DATE:		20250527
DATE AS OF CHANGE:		20250527

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HARVARD BIOSCIENCE INC
		CENTRAL INDEX KEY:			0001123494
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				043306140
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SD
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33957
		FILM NUMBER:		25989235

	BUSINESS ADDRESS:	
		STREET 1:		84 OCTOBER HILL RD
		CITY:			HOLLISTON
		STATE:			MA
		ZIP:			01746
		BUSINESS PHONE:		5088938999

	MAIL ADDRESS:	
		STREET 1:		84 OCTOBER HILL ROAD
		CITY:			HOLLISTON
		STATE:			MA
		ZIP:			01746
</SEC-HEADER>
<DOCUMENT>
<TYPE>SD
<SEQUENCE>1
<FILENAME>sd_52725.htm
<DESCRIPTION>FORM SD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">UNITED STATES</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">SECURITIES AND EXCHANGE COMMISSION</P>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Washington, D.C. 20549</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>FORM SD</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SPECIALIZED DISCLOSURE REPORT</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Harvard Bioscience, Inc.</B></P>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Exact name of the registrant as specified in its charter)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 33%"><FONT STYLE="font-size: 10pt"><B>DELAWARE</B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-33957</B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>04-3306140</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or Other Jurisdiction of Incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="padding-left: 18.5pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer Identification Number)</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font-size: 10pt"><B>84 October Hill Road, Holliston, MA</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>01746</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 89pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 3pt 0pt 0">Check the appropriate box to indicate the rule pursuant to which this form is being
filed, and provide the period to which the information in this form applies:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0; text-align: center"></TD><TD STYLE="text-align: center; width: 0.5in">&#9746;</TD><TD STYLE="text-align: justify">Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period
from January 1 to December 31, 2024.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0; text-align: right"></TD><TD STYLE="text-align: center; width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1)
for the fiscal year ended December&nbsp;31, 2024.</FONT></TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Section 1 - Conflict Minerals Disclosure</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Item 1.01 Conflict Minerals Disclosure and Report</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Conflict Minerals Disclosure</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">This Form&nbsp;SD of Harvard Bioscience, Inc. (the &ldquo;Company&rdquo;) is filed pursuant to Rule&nbsp;13p-1 promulgated under the Securities
Exchange Act of 1934, as amended, for the reporting period January&nbsp;1, 2024 to December&nbsp;31, 2024.</P>

<P STYLE="font-size: 10pt; margin: 0pt 41pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 41pt 0pt 0">A copy of the Company&rsquo;s Conflict Minerals Report is filed as Exhibit 1.01 hereto
and is publicly available at: http://investor.harvardbioscience.com/corporate-governance.cfm.</P>

<P STYLE="font-size: 10pt; margin: 0pt 41pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 41pt 0pt 0">The content of any website referred to in this Form SD or in the attached Conflict
Minerals Report is included for general information only and is not incorporated by reference in this Form SD or in the Conflict Mineral
Report.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Item 1.02 Exhibit</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Harvard Bioscience, Inc. is hereby filing its Conflict Minerals Report as Exhibit 1.01 to this
Form SD.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Section 3 &ndash; Exhibits</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Item 3.01 Exhibits</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The following exhibit is filed as part of this report.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><A HREF="exh_101.htm">Exhibit 1.01 Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD</A></P>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><B>SIGNATURES</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the duly authorized undersigned.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%; font-size: 10pt; font-weight: bold">Harvard Bioscience, Inc.</TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;(Registrant)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ John Fry</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">May 27, 2025</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; width: 3%; vertical-align: top">By:</TD>
    <TD STYLE="width: 42%">
    <P STYLE="font-size: 10pt; margin: 0pt 0">John Fry</P>
    <P STYLE="margin: 0pt; font-size: 10pt">Chief Legal Counsel</P></TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.01
<SEQUENCE>2
<FILENAME>exh_101.htm
<DESCRIPTION>EXHIBIT 1.01
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="text-align: right; font-size: 10pt; margin: 0pt 0 0pt 516pt"><B>Exhibit 1.01</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Harvard Bioscience, Inc.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Conflict Minerals Report</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>For the Year Ended December 31, 2024</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>This document contains forward-looking statements within the meaning of the federal securities
laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words
such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;intend,&rdquo; &ldquo;believe&rdquo; and similar expressions or statements that do not relate to historical matters. Forward-looking
statements include, but are not limited to, information concerning the Company&rsquo;s compliance efforts and expected actions identified
herein. These forward-looking statements are subject to various risks, uncertainties and assumptions, including, among other matters,
the Company&rsquo;s customers&rsquo; requirements to use certain suppliers, the Company&rsquo;s suppliers&rsquo; responsiveness and cooperation
with the Company&rsquo;s due diligence efforts, the Company&rsquo;s ability to implement improvements in its conflict minerals program
and the Company&rsquo;s ability to identify and mitigate related risks in its supply chain. Forward-looking statements do not guarantee
future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company&rsquo;s
control. Risks and other factors that could cause the Company&rsquo;s actual results to differ materially from those described in its
forward-looking statements include those described in the &ldquo;Risk Factors&rdquo; section of the Company&rsquo;s most recently filed
Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Forward-looking statements are based on the Company&rsquo;s
expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking
statements to reflect any change in expectations, even as new information becomes available.</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Conflict Minerals Disclosure</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 1pt 0pt 0">This Conflict Minerals Report (the &ldquo;Report&rdquo;) for Harvard Bioscience, Inc.
(&ldquo;Harvard Bioscience,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; or &ldquo;our&rdquo;) for the reporting
period from January 1, 2024 to December 31, 2024 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as
amended (the &ldquo;Rule&rdquo;). The SEC adopted the Rule to implement reporting and disclosure requirements related to conflict minerals
as directed by Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.The Rule imposes certain reporting
obligations on SEC registrants whose manufactured products contain conflict minerals that are necessary to the functionality or production
of their products. Conflict Minerals are defined as cassiterite, columbite-tantalite, gold, wolframite, and their derivatives, which are
limited to tin, tantalum, tungsten, and gold (&ldquo;Conflict Minerals&rdquo; or &ldquo;3TGs&rdquo;). These requirements apply to registrants
regardless of the geographic origin of the Conflict Minerals and whether or not such Conflict Minerals fund armed conflict.</P>

<P STYLE="font-size: 10pt; margin: 0pt 1pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 1pt 0pt 0">The information contained in this Report covers the Company and its subsidiaries. The
content of any website referred to in this Report is included for general information only and is not incorporated by reference in our
Form SD or this Report.</P>

<P STYLE="font-size: 10pt; margin: 0pt 1pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><U>Company Overview and Covered Products</U></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">We are a leading developer, manufacturer and seller of technologies,
products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery,
bio-production and preclinical testing for pharmaceutical and therapy development. Our products and services are sold globally to customers
ranging from academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">We have organized our product line activities into two product families:
Cellular and Molecular Technologies (&ldquo;CMT&rdquo;) and Preclinical.&nbsp;Our CMT product family is primarily composed of products
supporting research related to molecular, cellular organ and organoid technologies, with additional application in the emerging field
of bio-production of pharmaceuticals and therapeutics. The principal customers for our CMT products include academic and government laboratories,
biotechnology and pharmaceutical companies, and contract research organizations. Our Preclinical product family includes products that
support the preclinical research and testing phase for drug development, and in particular testing related to data collection and analysis
for safety and regulatory compliance. Preclinical products are primarily sold to pharmaceutical and biotechnology companies and CROs,
as well as to larger academic laboratories.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">We have determined that one or more 3TGs are necessary to the functionality
or production of CMT and Preclinical products that we manufactured, or contracted to manufacture, in the period covered by this Report.
As a result, our CMT and Preclinical product families are considered Covered Products for the purposes of this Report.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><U>Reasonable Country of Origin Inquiry</U></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">For purposes of this Report, &ldquo;Covered Countries&rdquo; refers to the Democratic Republic
of the Congo (the &ldquo;DRC&rdquo;) and adjoining countries, defined as any country that shares an internationally recognized border
with the DRC. In view of the above, we conducted a good faith, reasonable country of origin inquiry (&ldquo;RCOI&rdquo;) to determine
whether the 3TGs incorporated into our Covered Products originated in the Covered Countries or were from recycled or scrap sources.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Our supply chain is complex, and there are many third parties between us and the original sources
of the 3TGs. Furthermore, we do not purchase raw ore or unrefined 3TGs directly or make purchases from the Covered Countries. As a consequence,
we rely on our direct or Tier 1 suppliers to provide information on the origin of the 3TGs contained in our Covered Products. As part
of our RCOI, we surveyed relevant direct suppliers using the Conflict Minerals Reporting Template (&ldquo;CMRT&rdquo;) prepared by the
Responsible Minerals Initiative (&ldquo;RMI&rdquo;) (formerly the Conflict-Free Sourcing Initiative).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 1pt 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 1pt 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">We retained Assent Inc. (&ldquo;Assent&rdquo;), a third-party service provider, to assist us
carrying out the RCOI. We provided a list of relevant suppliers and parts to Assent for uploading to its Assent Compliance Manager SaaS
system, a tool that supports tracking of supplier communications and allows suppliers to upload completed CMRTs directly into the tool
for validation, assessment, and management. Assent engaged in follow-up communications with suppliers who did not respond to the survey
or whose responses were incomplete or required clarification, as appropriate.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><U>Due Diligence</U></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 1pt 0pt 0">Our due diligence measures were designed to conform, in all material
respects, with the framework in the Organization for Economic Co-operation and Development (OECD) Guidance and related supplements. Our
due diligence measures included the following:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 1pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0; text-align: right"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Establishing Strong Management Systems</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 1pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD><I>Conflict Minerals Policy.</I> In 2013, we adopted a written Conflict Minerals Policy relating to the use of conflict minerals in
our supply chain. A copy of our Conflict Minerals Policy is available at https://investor.harvardbioscience.com/corporate-governance.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD><I>Internal Management Team. </I>We have established a cross-functional Conflict Minerals Compliance Team led by the Company&rsquo;s
head of global engineering. The Conflict Minerals Compliance Team is responsible for implementing the conflict minerals compliance strategy
and briefing senior management about the results of these due diligence efforts. As noted above, we also engaged Assent to assist us in
evaluating supply chain information regarding 3TGs and in the development and implementation of due diligence steps that we undertake
without our suppliers.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">C.</TD><TD STYLE="text-align: justify; padding-right: 1pt"><I>Supplier Engagement. </I>We encourage our suppliers to implement responsible sourcing
of 3TGs and to provide accurate, complete, and timely information on the use of 3TGs in the products that they supply to us. Our in-scope
suppliers have also been provided with access to Assent&rsquo;s library of conflict minerals training and support resources. Also, Assent&rsquo;s
automated feedback process notifies suppliers of risks associated with their CMRT submission and serves to educate suppliers of certain
conflict mineral risks.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 1pt 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">D.</TD><TD><I>Grievance Mechanism</I>. Our Code of Business Conduct and Ethics includes procedures for reporting violations of our policies,
including our Conflict Mineral Policy, including procedures for reporting such matters on an anonymous basis.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Identifying and Assessing Risks in our Supply Chain.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">As discussed above, we identify relevant Tier 1 suppliers and rely on them to provide
the necessary information about the use of 3TGs in the products that they supply to us. We understand that our Tier 1 suppliers rely on
information provided by their suppliers to provide information the country of origin of 3TGs incorporated in our Covered Products. In
reviewing this information, we use risk assessment tools provided by our vendor Assent to assess 3TG-related supply chain risks.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0; text-align: right"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Designing and Implementing a Strategy to Respond to Identified Risks.</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 1pt 0pt 0.5in">We have developed a risk management plan, through which the
conflict minerals program is implemented, managed and monitored. Working through Assent, we contact non-responsive suppliers to outline
the importance of responding to CMRTs and compliance with relevant conflict minerals guidelines and the Company&rsquo;s expectations.
Feedback on suppliers&rsquo; submissions is given directly to respective suppliers, and educational resources are provided to assist suppliers
in implementing corrective actions or to improve their internal programs. The results of the program and risk assessment are shared with
our Conflict Minerals Compliance Team and senior management to ensure transparency within the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0; text-align: right"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Carrying Out Independent Third-Party Supply Chain Audits</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 1pt 0pt 0.5in">We do not have direct relationships with smelters or refiners
in our supply chain and, as a result, we do not perform direct audits of these entities. Instead, we rely on third-party audits of smelters
and refiners conducted through programs such as the Responsible Minerals Assurance Process (&ldquo;RMAP&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 1pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0; text-align: right"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">Reporting on Our Supply Chain Due Diligence</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">We publicly filed our Form SD and this Report with the SEC. A copy of these materials,
as well as our Conflict Minerals Policy, is publicly available on our website at https://investor.harvardbioscience.com/corporate-governance.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 1pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6.5in 0pt 0"><B><U>Diligence Results </U></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD>Survey Responses.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">As of May 19, 2025, there were 697 suppliers in scope of our conflict minerals program.
Of those suppliers, 330 (or 47.3%) provided a completed CMRT. Also as of May 19, 2025, there were 10 invalid supplier submissions that
could not be corrected.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Smelters or Refiners in Our Supply Chain</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 1pt 0pt 0.5in">Assent compared the list of smelters and refiners provided
in our suppliers&rsquo; responses to the lists of smelters maintained by RMI and, if a supplier indicated that a facility was certified
as conflict-free, confirmed that the facility was listed on RMI&rsquo;s list of validated conflict free smelters and refiners of 3TGs.
Our suppliers identified a total of 365 smelters and refiners that appear on the lists maintained by RMI. Of these 365 smelters and refiners,
(i) 232 are validated as conflict free by RMI or a cross-recognized initiative; (ii) based on information provided by RMI, a further 4
have agreed to undergo or are currently undergoing a third-party audit; (iv) 97 were not enrolled in the process to become compliant to
the RMAP; and (iii) 32 were identified as non-conformant under the RMAP.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0.7pt 0pt 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0.7pt 0pt 0.5in; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0.7pt 0pt 0.5in">As noted above, we submitted CMRTs to our Tier 1 suppliers.
The majority of the responses were provided at the company or division level, as opposed to the product or part number level. As a result,
we are unable to identify which smelters listed in these responses actually processed the 3TGs contained in our products. In addition,
the responses that we receive from our suppliers may yield inaccurate or incomplete information because our suppliers may not have received
accurate and complete information from their lower tier suppliers. Because we are not a member of the RMI, we do not have access to audit
reports or detailed findings of the third-party audits conducted as part of the RMI&rsquo;s RMAP or similar programs.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 1pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 1pt 0pt 0.5in">As a result, and after conducting the due diligence described
above, we are unable to conclusively determine the countries of origin of the 3TGs contained in our Covered Products.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><U>Future Steps</U></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">We have taken, or expect to take in reporting year 2025, the following steps to mitigate the
risk that 3TGs contained in our products finance or benefit armed groups in the Covered Countries:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Communicating our expectations concerning the responsible sourcing of 3TGs used in our products to our Tier 1 suppliers.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Encouraging our suppliers to obtain accurate, complete, and timely information on the use of 3TGs in the products that they supply
to us.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 13pt">Providing our suppliers with information and directing them to training resources to attempt to increase
the response rate and improve the content of the supplier survey responses.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 13pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 13pt 0pt 0.5in">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
